Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Background Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. We evaluated the incidence of hepatitis B reactivation and liver toxicity in patients with multiple myeloma (MM) who received high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (auto-HCT) at our institution.